These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21819622)

  • 21. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Dieci MV; Frassoldati A; Generali D; Bisagni G; Piacentini F; Cavanna L; Cagossi K; Puglisi F; Michelotti A; Berardi R; Banna G; Goubar A; Ficarra G; Griguolo G; Conte P; Guarneri V
    Breast Cancer Res Treat; 2017 Jun; 163(2):295-302. PubMed ID: 28289852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
    Fasching PA; Heusinger K; Haeberle L; Niklos M; Hein A; Bayer CM; Rauh C; Schulz-Wendtland R; Bani MR; Schrauder M; Kahmann L; Lux MP; Strehl JD; Hartmann A; Dimmler A; Beckmann MW; Wachter DL
    BMC Cancer; 2011 Nov; 11():486. PubMed ID: 22081974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients.
    Horimoto Y; Arakawa A; Tanabe M; Kuroda K; Matsuoka J; Igari F; Himuro T; Yoshida Y; Tokuda E; Shimizu H; Hino O; Saito M
    J Clin Pathol; 2015 Oct; 68(10):825-9. PubMed ID: 26060263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer.
    Robertson S; Stålhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J
    J Clin Pathol; 2018 Sep; 71(9):787-794. PubMed ID: 29588372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast Magnetic Resonance Imaging Can Predict Ki67 Discordance Between Core Needle Biopsy and Surgical Samples.
    Wei W; Ji Y; Tang Z; Huang X; Zhang W; Luo N
    J Magn Reson Imaging; 2023 Jan; 57(1):85-94. PubMed ID: 35648113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer.
    Saghir H; Veerla S; Malmberg M; Rydén L; Ehinger A; Saal LH; Vallon-Christersson J; Borg Å; Hegardt C; Larsson C; Haidar A; Hedenfalk I; Loman N; Kimbung S
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
    Hadad SM; Jordan LB; Roy PG; Purdie CA; Iwamoto T; Pusztai L; Moulder-Thompson SL; Thompson AM
    BMC Cancer; 2016 Sep; 16(1):745. PubMed ID: 27658825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
    Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
    Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.
    Faragalla H; Plotkin A; Barnes P; Lu FI; Kos Z; Mulligan AM; Bane A; Nofech Mozes S
    Curr Oncol; 2023 Mar; 30(3):3079-3090. PubMed ID: 36975446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
    Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
    PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative validation of the SP6 antibody to Ki67 in breast cancer.
    Zabaglo L; Salter J; Anderson H; Quinn E; Hills M; Detre S; A'Hern R; Dowsett M
    J Clin Pathol; 2010 Sep; 63(9):800-4. PubMed ID: 20671052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen.
    Cohen AL; Factor RE; Mooney K; Salama ME; Wade M; Serpico V; Ostrander E; Nelson E; Porretta J; Matsen C; Bernard P; Boucher K; Neumayer L
    Breast; 2017 Feb; 31():219-223. PubMed ID: 27915204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brief fixation does not hamper the reliability of Ki67 analysis in breast cancer core-needle biopsies: a double-centre study.
    Kalkman S; Bulte JP; Halilovic A; Bult P; van Diest PJ
    Histopathology; 2015 Feb; 66(3):380-7. PubMed ID: 25234295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.
    Assersohn L; Salter J; Powles TJ; A'hern R; Makris A; Gregory RK; Chang J; Dowsett M
    Breast Cancer Res Treat; 2003 Nov; 82(2):113-23. PubMed ID: 14692655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial.
    Newell M; Mackey JR; Bigras G; Alvarez-Camacho M; Goruk S; Ghosh S; Schmidt A; Miede D; Chisotti A; Postovit L; Baker K; Mazurak V; Courneya K; Berendt R; Dong WF; Wood G; Basi SK; Joy AA; King K; Meza-Junco J; Zhu X; Field C
    BMJ Open; 2019 Sep; 9(9):e030502. PubMed ID: 31530611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.
    Vörös A; Csörgő E; Nyári T; Cserni G
    Pathobiology; 2013; 80(3):111-8. PubMed ID: 23258384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study.
    Klauschen F; Wienert S; Schmitt WD; Loibl S; Gerber B; Blohmer JU; Huober J; Rüdiger T; Erbstößer E; Mehta K; Lederer B; Dietel M; Denkert C; von Minckwitz G
    Clin Cancer Res; 2015 Aug; 21(16):3651-7. PubMed ID: 25501130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.